Eli Lilly’s oral SERD combination regimen Inluriyo has received FDA approval for certain metastatic breast cancer patients as a second-line option. The regimen pairs Lilly’s selective estrogen receptor degrader with an additional partner therapy for an indication set described by the agency. The approval adds to Lilly’s effort to expand hormone-receptor targeted oncology beyond its existing launch footprint, with oral administration intended to improve practicality versus some infusion-based approaches. It also reinforces continued regulatory momentum for Lilly’s endocrine pipeline. For clinicians and payers, the decision will likely sharpen treatment sequencing discussions in metastatic disease where SERDs are increasingly central to strategy.